Many studies have demonstrated that osteopontin (OPN) contributes functionally to aggressive behaviour in many tumours including breast cancer.
This study aims to investigate its role as a simple biochemical marker easily measured in plasma of breast cancer patients to give an early signal for metastases and to detect its relationship to clinicopathological findings and survival.
We measured plasma OPN, CA15.3 and serum alkaline phosphatase (ALP) activity in 55 patients, 28 with early stage breast cancer and 27 with bone metastasis out of whom 20 had metastasis in other sites. The median age at diagnosis for non-metastatic cases was 60 years (range 35-85) and for metastatic cases was 45.5 years (range 32-59). In the non-metastatic group, 78.57% of the patients were histologically graded as grades I and II and 21.43% as grade III tumours. In the metastatic group, 81.48% of the patients had grades I and II and 18.52% had grade III tumours; 54% of patients in the non-metastatic group were at stage II and 46% were at stage III at presentation. All patients of group II had bone metastasis, 33% had liver metastases, 25.9% had lung metastasis and 14.8% had lymph node metastasis.
Patients with non-metastatic disease had a median OPN level of 55 ng/ml (range 54-150 ng/l), while those in the metastatic group had a median of 148.0 ng/l (range 56.0-156.0 ng/l), a difference which was statistically significant (P = 0.001). There was no statistically significant difference in the median levels of CA15.3 and ALP between both groups.
The median OPN level was significantly higher with serum ALP level above 90, progesterone receptor (PR) status, bone and visceral metastasis. Median OPN was not affected significantly by menopausal status (P-value 0.3), tumour grade (P-value 0.3), estrogen receptor (ER) status (P-value 0.7), pathological type (P-value 0.42) or serum CA15.3 level (P-value 0.6).
At the end of 12-year follow-up, 83% of the patients survived (92.3% in the non-metastatic versus 74.1% in the metastatic group). The estimated median survival for the whole study population at 12 years was 13 years (95% ). The estimated median survival was 13 years (95% CI 0) and 12 years (95% CI 4. 893-19.11) in patients with median OPN levels of <142 and ≥142, respectively, a difference which was not statistically significant (P = 0.343). No statistically significant difference in overall survival OS was noticed in relation to menopausal status (P = 0.7), pathological type (P = 0.4) and hormone receptor status (P = 0.3). At 6-year follow-up, it was found that OS was affected by the presence of visceral metastasis, tumour grade, serum plasma level of ALP and the serum level of CA15.3 (P = 0.0006, 0.007, 0.001 and 0.03, respectively). However, the presence of bone metastasis did not affect OS (P = 0.6).
Osteopontin level can be a simple biochemical marker easily measured in plasma of breast cancer patients to give early signals for metastases, but not a prognostic factor for survival.
Introduction
Breast cancer is by far the most common cancer among women from both developed and developing countries. It accounts for 22.9% of all female cancers. It is also the leading cause of cancer death in females accounting for 13.7% of their cancer-related mortality. The favourable incidence to mortality ratio (3:1) can be attributed to the more favourable survival in developed regions (3.7:1) than less developed regions (2.7:1) [1] . In Egypt, breast cancer is estimated to be the most common cancer among females accounting for 37.7% of total cancer cases. It is also the leading cause of cancerrelated mortality accounting for 29% of cancer deaths [2, 3] . These estimates are confirmed in many regional Egyptian cancer registries as well as in hospital-based frequencies [2, 3, 4] .
Metastasis is a multistep process requiring the expression of specific genes. In addition, it requires cooperation of numerous molecules and the coordinated expression of many protein products. Different carcinomas have distinct patterns of metastases. Breast cancer tumour cells disseminate very early to bone [5] . When breast cancer cells metastasise into the skeleton, they cause either osteolytic or osteoblastic lesions. Both lesions are often accompanied by bone pain and increased bone fragility causing extended suffering [6] . In general, 65-75% of breast cancer patients with advanced disease will develop bone relapse, leading to highly devastating conditions including pain, pathological fractures and spinal cord compression, ultimately decreasing the quality of life. Surveillance and prompt detection of early bone metastases can prevent the development of such complications [7] . Imaging techniques are now used to diagnose bone metastases, but they are expensive, and expose patients to toxic and radioactive compounds. This raises the importance of developing new bone metabolic markers that can aid in diagnose bone metastases [8] .
Osteopontin is a secreted integrin-binding glycophosphoprotein produced in a variety of tissues. Its association with cancer has been well documented. Many studies have demonstrated that OPN contributes functionally to aggressive cell behaviour, tumour progression and metastasis [9] . OPN is a phosphorylated glycoprotein found in all body fluids, extracellular matrix components and proteinaceous matrix of mineralised tissues. This protein was detected in approximately 90% of primary breast carcinomas and its overexpression is related with breast cancer evolution and metastases. Thus the synthesis of OPN by tumour cells may play a role in the promotion of bone metastases [10] . However, much less is known about the prognostic significance of OPN in early breast cancer or when OPN levels rise during breast cancer progression.
This study aims ultimately to investigate its role as a simple non-invasive biochemical marker that could be easily measured in plasma of breast cancer patients to give early signals for metastases and to detect a relationship between the OPN plasma level and clinicopathological findings and survival.
Patients and Methods
Fifty-five patients were included in this study. They were classified into two groups. A non-metastatic group comprising 28 patients with early stage breast cancer, without any evidence of metastatic disease, and a metastatic group comprising 27 patients with bone metastasis, with or without metastasis in other sites.
All patients involved in the present study were informed with a written consent explaining the design of the work, which was approved by the Institutional Review Board (IRB) ethical committee of the National Cancer Institute (NCI), which follows the rules of Helsinki IRB. Clinical data were recorded from the outpatient files in the medical oncology department of NCI-Cairo University. Patients were followed every 3 to 4 weeks for women on active chemotherapy and every 6 to 12 weeks for patients after chemotherapy or on hormone therapy. The median duration of follow-up was 12 years.
OPN level in plasma was determined using ELISA technique; the kit was purchased from Quantikine. Breast-cancer-associated antigen (CA15.3) in serum was determined using chemiluminescent-based technique of Elecsys 2010. The kit was purchased from Roche diagnostics, and serum ALP activity was determined according to the kinetic method of Deutschen Gesellschaft (1972), using the kit manufactured by Globe Diagnostics. The multiple receiver operating characteristic (ROC) curve was drawn to evaluate the cutoff point for the three markers to improve the specificity and sensitivity of the studied parameters (Table 1) .
All patients were subjected to routine laboratory investigations including complete blood picture, liver function and kidney function.
Statistical methods
Data was analysed using IBM SPSS advanced statistics version 20 (SPSS Inc., Chicago,Illinois). The ROC curve was drawn, to improve the specificity and sensitivity of the studied parameters. Chi-square test (Fisher's exact test) was used to examine the relation between qualitative variables. Survival analysis was done using the Kaplan-Meier method and comparison between two survival curves was done using the log-rank test. A p-value <0.05 was considered significant.
Results
We measured plasma OPN in 55 patients, 28 with early stage breast cancer and 27 with bone metastasis out of whom 20 had, in addition, metastasis in sites other than bone. The median age at the time of diagnosis for nonmetastatic cases was 60 years (range 35-85) and for metastatic cases was 45.5 years (range 32-59). In the non-metastatic group, 82.14% of patients had invasive duct carcinoma, 7.14% had invasive lobular carcinoma and 10.72% had mixed invasive duct carcinoma and invasive lobular carcinoma, while in the metastatic group 85.18% of the patients had invasive duct carcinoma, 7.14% had invasive lobular carcinoma and 7.41% had mixed invasive duct and lobular carcinoma. In the non-metastatic group, 78.57% of the patients were histologically graded as grades I and II tumours and 21.43% as grade III tumours. In the metastatic group, 81.48% of the patients were graded as grades I and II tumours and 18.52% as grade III tumours.
As regards stage of the disease, 54% of patients in the non-metastatic group were stage II and 46% were stage III at presentation. All patients of group II had bone metastasis, 33% had liver metastases, 25.9% had lung metastasis and 14.8% had lymph node metastasis; these data are detailed in Table 2 .
The median OPN level in the whole study population was 142 ng/l (range 54.0-156 ng/l). Patients with non-metastatic disease had a median OPN level of 55.0 ng/ml (range 54.0-150.0 ng/ml), while those in the metastatic group had a median of 148.0 ng/l (range 56.0-156.0 ng/l). The level of OPN in plasma of patients with metastasis was found to be significantly higher as compared to its corresponding level in non-metastatic patients (p = 0.001). There was no statistically significant difference in the median levels of CA15.3 and ALP between both groups (Table 3) .
On analysing the relation between the median OPN level and different prognostic factors in the whole study population, it was found that the median OPN level was significantly higher with serum ALP level above 90 and from 40 to 90, PR status, bone and visceral metastasis. Median OPN was not affected significantly by menopausal status (P-value 0.3), tumour grade (P-value 0.3), ER status (P-value 0.7), pathological typing (P-value 0.42) or serum CA15.3 level (P-value 0.6); see Table 4 .
We tested whether the survival of the patients was related to the OPN plasma level. Fig. 1 shows the Kaplan-Meier adjusted survival estimates of patients grouped into two according to the median OPN level (lower than 142 and ≥142). At the end of 12-year follow-up for the whole study population, 83% of the patients survived (92.3% in non-metastatic versus 74.1% in metastatic patients). The estimated median survival for the whole study population at 12 years was 13 years. (95% ). The estimated median survival was 13 years (95% CI 0) and 12 years (95% CI 4. 893-19.11) in patients with median OPN levels of <142 and ≥142, respectively. The difference was not statistically significant (P = 0.343). No statistically significant difference in OS was noticed in relation to menopausal status (P = 0.7), pathological typing (P = 0.4) and hormone receptor status (P = 0.3). At 6-year follow-up, it was found that OS was affected by the presence of visceral metastasis, tumour grade, serum plasma level of ALP and the serum level of CA15.3 (P = 0.0006, 0.007, 0.001 and 0.03, respectively). However the presence of bone metastasis did not affect OS (P = 0.6).
Discussion
Osteopontin is a matricellular protein produced by multiple tissues in the human body and is most abundant in bone [11] . Several studies have shown that OPN levels may be elevated in cancer, both in tumour tissue and in patients' blood [12] . Osteopontin is highly expressed in a variety of tumours and appears to be a prognostic factor correlating with poor prognosis and reduced survival [13] . It has been demonstrated that the plasma OPN level is significantly higher in patients with metastatic breast cancer compared to patients who are on clinical follow-up after completion of adjuvant therapy for early breast cancer [14, 15, 16] . Fifty-five patients were included in this study, 28 presented with stages II or III and 27 patients with stage IV; stage I is rare in Egyptian patients with breast cancer presenting to NCI. Our median OPN level for metastatic patients was 148 ng/l (range 56-156 ng/l), [15] . In this study, a statistically significant association between the OPN level and visceral metastases was demonstrated and OS was statistically lower in this group of patients (p = 0.0006). There was also a relation between OS and high tumour grade (p = 0.007) and between high CA15.3 serum level and OS (p = 0.03). No relation was found between OS and menopausal status, pathological type or hormonal status.
Conclusion
The OPN level can be an easily measured biochemical marker. It can be used as an early signal for metastases, but not a prognostic factor for survival. This raises the importance of conducting more clinical trials addressing this issue. 
